Pulmatrix closed a $1 million private placement of Series B Convertible Preferred Stock with an Eos affiliate as part of its planned merger with Eos SENOLYTIX on April 16, 2026.
Key takeaways
Closed private placement of Series B Preferred Stock for $1 million gross proceeds on April 16, 2026.
Investor is affiliate of Eos SENOLYTIX, part of planned merger process.
Convertible into common stock at $2.20 per share, exercisable 90 days post-issuance.
Proceeds for working capital and general corporate purposes.
Exempt under Section 4(a)(2) and Rule 506 of Regulation D.